

*Final Terms dated 21 April 2021  
BrokerCreditService Structured Products plc*

*(incorporated in The Republic of Cyprus)*

*(the "Issuer")*

*Issue of Series 167 USD 1,500,000 Share Linked Notes (Autocall Standard Notes with Snowball  
Digital Coupon) due 2023*

*under the EUR 10,000,000,000 Euro Medium Term Note Programme (the "Programme")*

Any person making or intending to make an offer of the Notes may only do so in circumstances in which no obligation arises for the Issuer or the Dealer to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or to supplement a prospectus pursuant to Article 23 of the Prospectus Regulation, in each case, in relation to such offer.

Neither the Issuer nor the Dealer has authorised, nor do they authorise, the making of any offer of Notes in any other circumstances.

**MiFID II product governance / Retail investors, professional investors and ECPs target market** – Solely for the purposes of the manufacturer's product approval process, the target market assessment in respect of the Notes has led to the conclusion that: (i) the target market for the Notes is eligible counterparties, professional clients and retail clients each as defined in Directive 2014/65/EU (as amended, "**MiFID II**"); (ii) all channels for distribution to eligible counterparties and professional clients are appropriate; and (iii) the following channels for distribution of the Notes to retail clients are appropriate - investment advice, portfolio management, non-advised sales and pure execution services - subject to the distributor's suitability and appropriateness obligations under MiFID II, as applicable. Any person subsequently offering, selling or recommending the Notes (a "**distributor**") should take into consideration the manufacturer's target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the Notes (by either adopting or refining the manufacturer's target market assessment) and determining appropriate distribution channels, subject to the distributor's suitability and appropriateness obligations under MiFID II, as applicable.

## PART A - CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Conditions (the "**Conditions**") set forth under the sections entitled "*Terms and Conditions of the Notes*", "*Annex 1 - Additional Terms and Conditions for Payouts*" and "*Annex 3 - Additional Terms and Conditions for Share Linked Notes*" in the Base Prospectus dated 6 July 2020 and the Supplement to the Base Prospectus dated 9 October 2020 which together constitute a base prospectus for the purposes of the Prospectus Regulation (the "**Base Prospectus**"). This document constitutes the Final Terms of the Notes described herein for the purposes of the Prospectus Regulation, and must be read in conjunction with the Base Prospectus in order to obtain all the relevant information.

Full information on the Issuer and the offer of the Notes is only available on the basis of the combination of these Final Terms and the Base Prospectus. The Base Prospectus, these Final Terms and the Supplement to the Base Prospectus (in each case, together with any documents incorporated therein by reference) are available for viewing at, and copies may be obtained from, Citibank, N.A., London Branch (in its capacity as Fiscal Agent). The Base Prospectus and the Supplement to the Base Prospectus will also be available on the website of Euronext Dublin ([www.ise.ie](http://www.ise.ie)) and these Final Terms will be available for viewing on the website of Euronext Dublin. A copy of these Final Terms, the Base Prospectus and the Supplement to the Base Prospectus will be sent free of charge by the Issuer to any investor requesting such documents. A summary of the Notes is annexed to these Final Terms.

The Base Prospectus, these Final Terms and the Supplement to the Base Prospectus are available for viewing at, and copies may be obtained from, the Fiscal Agent.

The expression "**Prospectus Regulation**" means Regulation (EU) 2017/1129.

1.	Issuer:	BrokerCreditService Structured Products plc
2.	(i) Series Number:	167
	(ii) Tranche Number:	1
3.	Specified Currency:	U. S. Dollars (" <b>USD</b> ")
4.	Aggregate Nominal Amount:	
	(i) Series:	USD 1,500,000
	(ii) Tranche:	USD 1,500,000
5.	Issue Price of Tranche:	100 per cent. of the Aggregate Nominal Amount
6.	Minimum Trading Size:	Not Applicable
7.	(i) Specified Denominations:	USD 1,250
	(ii) Calculation Amount:	USD 1,250
8.	Issue Date and Interest Commencement Date:	21 April 2021
9.	Maturity Date:	30 April 2023
10.	Form of Notes:	Registered
11.	Interest Basis:	Share Linked Interest



		(further particulars specified below)
12.	Coupon Switch:	Not Applicable
13.	Redemption/Payment Basis:	Share Linked Redemption
		Payout Switch: Not applicable
14.	Payout Switch:	Not Applicable
15.	Put/Call Options:	Not Applicable
16.	Settlement Currency:	USD
17.	Knock-in Event:	Not Applicable
18.	Knock-out Event:	Not Applicable
19.	Method of distribution:	Non-syndicated
20.	Hybrid Securities:	Not Applicable

**PROVISIONS RELATING TO INTEREST (IF ANY) PAYABLE**

21.	Interest:	Applicable
	(i) Specified Period:	Not applicable
	(ii) Interest Period(s):	From (and including) an Interest Period End Date (or the Interest Commencement Date in the case of the first Interest Period) to (but excluding) the next following Interest Period End Date
	(iii) Interest Period End Date(s):	30 January, 30 April, 30 July and 30 October in each year, commencing on 30 July 2021 up to and including the Maturity Date
	(iv) Business Day Convention for Interest Period End Date(s):	Following
	(v) Interest Payment Date(s):	Each Interest Period End Date
	(vi) Business Day Convention for Interest Payment Date(s):	Following
	(vii) Party responsible for calculating the Rate(s) of Interest and Interest Amount(s) (if not the Calculation Agent):	Calculation Agent
	(viii) Margin(s):	Not applicable
	(ix) Minimum Interest Rate:	Not applicable
	(x) Maximum Interest Rate:	Not applicable

- |        |  |                                    |
|--------|--|------------------------------------|
| (xi)   | Day Count Fraction:  | Not applicable                     |
| (xii)  | Determination Dates:   | Not applicable                     |
| (xiii) | Accrual to Redemption:   | Not applicable                     |
| (xiv)  | Rate of Interest:  | Not applicable                     |
| (xv)   | Coupon Rate: (Include one or more of the following if applicable): | Snowball Digital Coupon applicable |
| (xvi)  | Rate(i):   | 2.5 per cent. per Interest Period  |

Snowball Digital Coupon applicable:

- |       |                                    |  |
|-------|------------------------------------|--|
| (i)   | Snowball Digital Coupon Condition: | Equal to or greater than   |
| (ii)  | SPS Coupon Valuation Date:         | 23 January, 23 April, 23 July and 23 October in each year, commencing on 23 July 2021 up to and including 23 April 2023 (or, if any such day is not a Scheduled Trading Day, the next following Scheduled Trading Day) |
| (iii) | SPS Coupon Valuation Period:       | Not applicable   |
| (iv)  | Multiple Barriers:                 | Not applicable   |
| (v)   | Snowball Barrier Value:            | Worst Value  |
| (vi)  | Snowball Level:                    | 65 per cent.   |
| (vii) | Rate(i) for each Snowball Level:   | Not applicable   |

#### VALUATION METHODOLOGIES FOR COUPON PAYMENTS

- |       |   |  |
|-------|---|--|
| 22.   | Payout Conditions:                        | Applicable   |
|       | Worst Value is applicable:                |  |
| (i)   | SPS Valuation Date:                       | SPS Coupon Valuation Date  |
| (ii)  | Underlying Reference:                     | Share Linked   |
| (iii) | Underlying Reference Closing Price Value: | Closing Price  |
| (iv)  | Closing Price:                            | As per Annex 3 ( <i>Additional Terms and Conditions for Share Linked Notes</i> ) |
| (v)   | Strike Date:                              | Not applicable   |
| (vi)  | Strike Days:                              | As per Strike Period below   |
| (vii) | Averaging Date Consequences:              | Applicable: Postponement applicable  |

	(viii)	Scheduled Custom Index Business Day:	Not applicable
	(ix)	Index Sponsor:	Not applicable
	(x)	Underlying Reference Strike Price:	Strike Price Minimum Value
	(xi)	FX Conversion:	Not applicable
	(xii)	Underlying Reference FX Level:	Not applicable
	(xiii)	Underlying Reference FX Strike Level:	Not applicable
	(xiv)	Strike Period:	Each of the following Strike Days: 27 April 2021, 4 May 2021, 11 May 2021, 18 May 2021 and 25 May 2021 (or, if any such day is not a Scheduled Trading Day, the next following Scheduled Trading Day)
	(xv)	Barrier Percentage Strike Price:	Not applicable
23.		Fixed Rate Provisions:	Not Applicable
24.		Floating Rate Provisions:	Not Applicable
25.		Screen Rate Determination:	Not Applicable
26.		ISDA Determination:	Not Applicable
27.		Zero Coupon Provisions:	Not Applicable
28.		Index Linked Interest Provisions:	Not Applicable
29.		Share Linked Interest Provisions:	Applicable
	(i)	Shares/ADR:	<ol style="list-style-type: none"> <li>1. Biogen Inc</li> <li>2. BioMarin Pharmaceutical Inc</li> <li>3. Helmerich &amp; Payne Inc</li> </ol>
	(ii)	Relative Performance Basket:	Applicable
	(iii)	Share Currency:	USD
	(iv)	ISIN of Share(s):	<ol style="list-style-type: none"> <li>1. US09062X1037</li> <li>2. US09061G1013</li> <li>3. US4234521015</li> </ol>
	(v)	Screen Page/Exchange Code:	The following pages on Bloomberg Business:



		1. BIIB UW Equity
		2. BMRN UW Equity
		3. HP UN Equity
(vi)	Averaging:	Averaging does not apply to the Notes.
(vii)	Strike Date:	Not applicable
(viii)	Interest Valuation Time:	Scheduled Closing Time
(ix)	Interest Valuation Date(s):	Each SPS Coupon Valuation Date
(x)	Observation Date(s):	Not applicable
(xi)	Observation Period:	Not applicable
(xii)	Exchange Business Day:	(All Shares Basis)
(xiii)	Scheduled Trading Day:	(All Shares Basis)
(xiv)	Exchange(s):	The relevant Exchanges are the New York Stock Exchange with respect to Helmerich & Payne Inc, Nasdaq with respect to BioMarin Pharmaceutical Inc and Biogen Inc.
(xv)	Related Exchange(s):	All Exchanges
(xvi)	Weighting:	Not applicable
(xvii)	Valuation Time:	Scheduled Closing Time
(xviii)	Share Correction Period:	One Settlement Cycle
(xix)	Optional Additional Disruption Events:	The following Optional Additional Disruption Events apply to the Notes:  Increased Cost of Hedging  Insolvency Filing
(xx)	Trade Date:	21 April 2021
(xxi)	Market Disruption:	Specified Maximum Days of Disruption will be equal to eight
(xxii)	Tender Offer:	Applicable
(xxiii)	Listing Change:	Applicable
(xxiv)	Listing Suspension:	Applicable
(xxv)	Illiquidity:	Not applicable
(xxvi)	Delayed Redemption on the Occurrence of an Extraordinary Event:	Not applicable

30.	Commodity Linked Interest Provisions:	Not Applicable
31.	Fund Linked Interest Provisions:	Not Applicable
32.	ETI Linked Interest Provisions:	Not Applicable
33.	Foreign Exchange (FX) Rate Linked Interest Provisions:	Not Applicable
34.	Underlying Interest Rate Linked Interest Provisions:	Not Applicable
35.	Additional Business Centre(s):	Moscow and Limassol (Cyprus)

**PROVISIONS RELATING TO REDEMPTION**

36.	Final Redemption Amount:	Final Payout
37.	Final Payout:	Applicable
	Autocall Standard Notes	
(i)	FR Barrier Value:	Worst Value
(ii)	Final Redemption Condition Level:	100 per cent.
(iii)	FR Exit Rate:	0 per cent.
(iv)	SPS Knock-in Valuation:	Applicable: less than Knock-in Level: 65 per cent.
(v)	Knock-in Determination Day:	23 April 2023 (or, if such day is not a Scheduled Trading Day, the next following Scheduled Trading Day)
(vi)	Knock-in Determination Period:	Not applicable
(vii)	Knock-in Value:	Worst Value
(viii)	Coupon Airbag Percentage:	0 per cent.
(ix)	Final Redemption Value:	Worst Value
(x)	SPS Valuation Date:	Knock-in Determination Day
(xi)	SPS Redemption Valuation Date(s):	Knock-in Determination Day
(xii)	SPS FR Barrier Valuation Date(s):	Knock-in Determination Day

**VALUATION METHOD FOR REDEMPTION PAYMENT:**

38.	Payout Conditions:	Applicable
-----	--------------------	------------

Worst Value is applicable:

- |        |  |   |
|--------|--|---|
| (i)    | SPS Valuation Date:                        | SPS FR Barrier Valuation Date and Knock-in Determination Day and Automatic Early Redemption Valuation Date  |
| (ii)   | SPS Redemption Valuation Date(s):          | Not applicable  |
| (iii)  | Underlying Reference:                      | Share Linked  |
| (iv)   | Underlying Reference Closing Price Value:  | Closing Price   |
| (v)    | Closing Price:                             | As per Annex 3 ( <i>Additional Terms and Conditions for Share Linked Notes</i> )  |
| (vi)   | Strike Date:                               | Not applicable  |
| (vii)  | Scheduled Custom Index Business Day:       | Not applicable  |
| (viii) | Index Sponsor:                             | Not applicable  |
| (ix)   | Underlying Reference Strike Price:         | Strike Price Minimum Value  |
| (x)    | FX Conversion:                             | Not applicable  |
| (xi)   | Underlying Reference FX Level:             | Not applicable  |
| (xii)  | Underlying Reference FX Strike Level:      | Not applicable  |
| (xiii) | Strike Period:                             | Each of the following Strike Days: 27 April 2021, 4 May 2021, 11 May 2021, 18 May 2021 and 25 May 2021 (or, if any such day is not a Scheduled Trading Day, the next following Scheduled Trading Day and with Averaging Date Consequences applicable (Postponement applicable)) |
| (xiv)  | Barrier Percentage Strike Price:           | Not applicable  |
| 39.    | Automatic Early Redemption:                | Applicable  |
| (i)    | Automatic Early Redemption Event:          | Automatic Early Redemption Event 1: "greater than or equal to"  |
| (ii)   | Automatic Early Redemption Valuation Time: | Scheduled Closing Time  |
| (iii)  | Automatic Early Redemption Payout:         | SPS Automatic Early Redemption Payout 1:<br>AER Redemption Percentage: 100 per cent.  |



		AER Exit Rate: AER Rate
(iv)	Automatic Early Redemption Date(s):	Each Interest Payment Date (except for the Interest Payment Date scheduled to fall on the Maturity Date)
(v)	Automatic Early Redemption Price:	100 per cent.
(vi)	Automatic Early Redemption Percentage:	Not applicable
(vii)	Automatic Early Redemption Percentage Up:	Not applicable
(viii)	Automatic Early Redemption Percentage Down:	Not applicable
(ix)	AER Rate:	0 per cent.
(x)	AER Exit Rate:	Not applicable
(xi)	AER Screen Page:	Not applicable
(xii)	AER Specified Time:	Not applicable
(xiii)	AER Reference Rate Determination Date(s):	Not applicable
(xiv)	AER Margin:	Not applicable
(xv)	Automatic Early Redemption Valuation Date(s):	Each SPS Coupon Valuation Date (except for the SPS Coupon Valuation Date scheduled to fall on 23 April 2023)
(xvi)	Underlying Reference Level:	Not applicable
(xvii)	SPS AER Valuation:	Applicable
		SPS AER Value 1: Worst Value
(xviii)	AER Event 1 Underlyings:	See item 44(i) below
(xix)	AER Event 2 Underlyings:	Not applicable
(xx)	AER Event 1 Basket:	Not applicable
(xxi)	AER Event 2 Basket:	Not applicable
(xxii)	AER Day Count Fraction:	Not applicable
(xxiii)	Cut-off Date:	Not applicable
(xxiv)	Early Redemption Leverage Factor:	Not applicable

	(xxv)	QR Price in respect of the Basket Price:	Not applicable
	(xxvi)	QR Price in respect of the Final Price:	Not applicable
	(xxvii)	QR Price in respect of the Initial Price:	Not applicable
40.		Issuer Call Option:	Not Applicable
41.		Put Option:	Not Applicable
42.		Aggregation:	Not Applicable
43.		Index Linked Redemption Amount:	Not Applicable
44.		Share Linked Redemption Amount:	Applicable
	(i)	Share:	<ol style="list-style-type: none"> <li>1. Biogen Inc</li> <li>2. BioMarin Pharmaceutical Inc</li> <li>3. Helmerich &amp; Payne Inc</li> </ol>
	(ii)	Relative Performance Basket:	Applicable
	(iii)	Share Currency:	USD
	(iv)	ISIN of Share(s):	<ol style="list-style-type: none"> <li>1. US09062X1037</li> <li>2. US09061G1013</li> <li>3. US4234521015</li> </ol>
	(v)	Screen Page/Exchange Code:	<p>The following pages on Bloomberg Business:</p> <ol style="list-style-type: none"> <li>1. BIIB UW Equity</li> <li>2. BMRN UW Equity</li> <li>3. HP UN Equity</li> </ol>
	(vi)	Strike Date:	Not applicable
	(vii)	Averaging:	Averaging does not apply to the Notes.
	(viii)	Redemption Date:	Valuation 23 April 2023
	(ix)	Observation Date(s):	Not applicable
	(x)	Observation Period:	Not applicable
	(xi)	Exchange Business Day:	(All Shares Basis)

	(xii)	Scheduled Trading Day:	(All Shares Basis)
	(xiii)	Exchange(s):	The relevant Exchanges are the New York Stock Exchange with respect to Helmerich & Payne Inc, Nasdaq with respect to BioMarin Pharmaceutical Inc and Biogen Inc.
	(xiv)	Related Exchange(s):	All Exchanges
	(xv)	Weighting:	Not applicable
	(xvi)	Valuation Time:	Scheduled Closing Time
	(xvii)	Share Correction Period:	One Settlement Cycle
	(xviii)	Optional Additional Disruption Events:	The following Optional Additional Disruption Events apply to the Notes:  Increased Cost of Hedging  Insolvency Filing
	(xix)	Trade Date:	21 April 2021
	(xx)	Market Disruption:	Specified Maximum Days of Disruption will be equal to eight
	(xxi)	Tender Offer:	Applicable
	(xxii)	Listing Change:	Applicable
	(xxiii)	Listing Suspension:	Applicable
	(xxiv)	Illiquidity:	Not applicable
	(xxv)	Delayed Redemption on the Occurrence of an Extraordinary Event:	Not applicable  Principal Protected Termination Amount:  Not applicable
45.		Commodity Linked Redemption Amount:	Not Applicable
46.		Fund Linked Redemption Amount:	Not Applicable
47.		Credit Linked Notes:	Not Applicable
48.		ETI Linked Redemption Amount:	Not Applicable
49.		Foreign Exchange (FX) Rate Linked Redemption Amount:	Not Applicable
50.		Underlying Interest Rate Linked Redemption Amount:	Not Applicable
51.		Early Redemption Amount:	



	Early Redemption Amount(s):	Market Value less Costs
52.	Provisions applicable to Physical Delivery:	Not Applicable
53.	Variation of Settlement:	
	(i) Issuer's option to vary settlement:	The Issuer does not have the option to vary settlement in respect of the Notes.
	(ii) Variation of Settlement of Physical Delivery Notes:	Not applicable

#### GENERAL PROVISIONS RELATING TO THE NOTES

54.	Form of Notes:	Registered Notes  Global Registered Note exchangeable for Individual Note Certificates in the limited circumstances described in the Global Registered Note
55.	New Global Note:	No
56.	Additional Financial Centre(s) or other special provisions relating to payment dates:	Moscow and Limassol (Cyprus)
57.	Talons for future Coupons to be attached to Definitive Notes (and dates on which such Talons mature):	No
58.	Details relating to Partly Paid Notes: amount of each payment comprising the Issue Price and date on which each payment is to be made and, if different from those specified in the Temporary Global Note, consequences of failure to pay, including any right of the Issuer to forfeit the Notes and interest due on late payment:	Not Applicable
59.	Details relating to Notes redeemable in instalments: amount of each instalment, date on which each payment is to be made:	Not Applicable
60.	Calculation Agent:	BrokerCreditService (Cyprus) Limited
61.	Date board approval for issuance of Notes obtained:	20 April 2021
62.	Relevant Benchmark:	Not Applicable

Signed on behalf of the Issuer:

By:

Duly authorised



Eugenio Baglazzi's  
Director

## PART B - OTHER INFORMATION

### 1. LISTING AND ADMISSION TO TRADING

- (i) Listing and admission to trading: Application has been made to Euronext Dublin for the Notes to be admitted to trading on its regulated market with effect from on or about the Issue Date.
- (ii) Estimate of total expenses related to admission to trading: EUR 1,000

### 2. INTERESTS OF NATURAL AND LEGAL PERSONS INVOLVED IN THE ISSUE/OFFER

Save for any fees payable to the Dealer, so far as the Issuer is aware, no person involved in the offer of the Notes has an interest material to the offer. The Dealer and its affiliates have engaged, and may in the future engage, in investment banking and/or commercial banking transactions with, and may perform other services for, the Issuer and its affiliates in the ordinary course of business.

### 3. REASONS FOR THE OFFER, ESTIMATED NET PROCEEDS AND TOTAL EXPENSES

- (i) Reasons for the offer: See the "Use of Proceeds" wording in the Base Prospectus
- (ii) Estimated net proceeds: USD 1,500,000
- (iii) Estimated total expenses: Nil save for the expenses referred to in paragraph 1(ii) above.

### 4. PERFORMANCE OF SHARES AND OTHER INFORMATION CONCERNING THE UNDERLYING REFERENCES

Information of past and future performance and volatility of the Shares can be found on the Screen Page specified above for the relevant Share.

### 5. OPERATIONAL INFORMATION

- ISIN: XS2333597859
- Common Code: 233359785
- Delivery: Free of payment
- Names and addresses of additional Paying Agent(s) (if any): Not Applicable
- Additional U.S. federal income tax considerations: The Notes are not subject to U.S. federal withholding tax under Section 871(m)

### 6. DISTRIBUTION

- (i) Method of distribution: Non-syndicated
- (ii) If syndicated: Not applicable



- |       |   |  |
|-------|---|--|
| (iii) | If non-syndicated, name and address of Dealer:  | BrokerCreditService (Cyprus) Limited (address: Spyrou Kyprianou & 1 Oktovriou, 1 Vashiotis Kalande Offices, 2nd floor Mesa Geitonia, 4004, Limassol, Cyprus) |
| (iv)  | Indication of the overall amount of the underwriting commission and of the placing commission:      | Not applicable   |
| (v)   | US Selling Restrictions:<br><br>(Categories of potential investors to which the Notes are offered): | Reg. S Compliance Category 2; TEFRA not applicable   |
| (vi)  | Prohibition of Sales to EEA and UK Retail Investors:  | Not applicable   |
| (vii) | Public Offer:   | Not applicable   |





AGIA ZONI CENTER, Flat/Office 103, 3027 Limassol, Cyprus. Its LEI is 213800W4XQFCUX7HFM81.

*Principal activities:*

The Issuer is a special purpose vehicle which acts as an investment and financing company for the Group (being FG BCS Ltd. together with its consolidated subsidiaries, the "Group") and issues notes under the Programme.

The Issuer conducts trading operations in the international securities markets, which include entering into transactions with market counterparties and related parties that are members of the Group. These transactions include, but are not limited to, repo transactions, loans and transactions in securities in the international capital markets including exchanges and OTC markets. The Issuer also conducts investment activities in different types of bonds of both Russian and international issuers.

*Major Shareholders:*

The Issuer is a subsidiary of FG BCS LTD, which holds 99.96% of the issued shares of the Issuer. FG BCS Ltd is incorporated and domiciled in Cyprus. The ultimate shareholder owning and controlling the Issuer is Oleg Mikhasenko, who is the sole ultimate beneficial owner of the Group.

*Key managing directors:*

Sergei Kosarev and Evgenios Bagiazidis (executive directors).

Franz Hep and Dimitra Karkalli (non-executive directors).

*Statutory auditors:*

Yiallourides & Partners Ltd, chartered accountants of Sotiris Tofini, 4, AUDEH QUARTERS, Floor 1, Flat 102 & 103, St. Athanasius, 4102, Limassol, Cyprus

*What is the key financial information regarding the Issuer?*

The summary information in the tables below is extracted from the audited and consolidated financial statements of the Issuer as at and for the year ended 31 December 2018, the audited and consolidated financial statements of the Issuer as at and for the year ended 31 December 2019, the unaudited and consolidated financial statements of the Issuer as at and for the half year period ended 30 June 2019 and the unaudited and consolidated financial statements of the Issuer as at and for the half year period ended 30 June 2020 (the "Financial Statements").

In respect of the Financial Statements, the Issuer has adopted all of the new and revised International Financial Reporting Standards ("IFRS") that are relevant to it and are effective for accounting periods beginning on 1 January 2017, including IFRS 9 "Financial Instruments".

**Comparative Annual Financial Data – In RUB**

	31/12/2019	31/12/2018	For the 6 months ended 30/06/2020 (unaudited)	For the 6 months ended 30/06/2019 (unaudited)
<i>Table 1</i>				
<b>Income statement</b>				
Net profit or loss	3,052,016,112	5,077,480,753	4,217,532,683	2,846,704,671

*Table 2*

**Balance sheet**



Total Liabilities	179,406,365,249	242,011,482,393	195,175,207,968	-
Cash at bank and in hand	155,661,730	106,562,187	147,827,340	-

*Table 3*

**Cash flow statement**

Net cash generated from operating activities	5,203,083,462	5,323,955,066	5,998,869,142	16,515,995,159
Net cash used in financing activities	(6,501,396,943)	(7,054,876,773)	(115,559,885)	(6,500,024,389)
Net cash generated from investing activities	1,347,386,019	1,675,616,687	(5,895,984,234)	(9,935,125,642)

***What are the key risks that are specific to the Issuer?***

***Credit risk***

As part of its trading operations, the Issuer enters into loans, OTC derivatives, securities lending transactions and other financial transactions with a number of counterparties. Credit risk is the risk of loss that the Issuer may incur as a result of borrowers or other counterparties of the Issuer defaulting on their payment obligations in respect of such transactions, including the risks attaching to the Issuer's customers having financial difficulties and risks relating to large exposures, which could impact the Issuer's ability to meet its obligations under the Notes.

***Market risk***

The Issuer faces market risks as an inherent part of its business. The Issuer's market risk relates to the risk of loss that the Issuer may incur because of adverse developments in market values resulting from fluctuations in interest rates, credit spreads, foreign currency exchange rates and equity and commodity prices. The performance of financial markets may cause changes in the value of the Issuer's investment and trading books which may adversely affect the Issuer's financial position, including reducing its revenue which, in turn, could prevent the Issuer from fulfilling its payment obligations under the Notes.

***Liquidity risk***

The Issuer is subject to liquidity risk, being the risk that a lack of funding prevents the Issuer from being able to finance its activities (i.e. to ensure the growth of its assets or perform its obligations as they fall due). The Issuer is subject to the following types of liquidity risk:

- i. physical liquidity risk, being the risk of default by the Issuer on its liabilities to counterparties in any currency because of a shortage of cash or non-cash funds; and
- ii. structural liquidity risk (i.e. concentration risk), being the risk of a significant deterioration of the Issuer's physical or regulatory liquidity due to an imbalance in the Issuer's asset and liability structure, which arises from a mismatch between the maturity of the Issuer's assets and liabilities. Although an unmatched position potentially enhances profitability, it can also increase the risk of losses for the Issuer.

If the Issuer is unable to finance its activities due to a lack of liquidity, this could lead creditors to form a negative view of Issuer's liquidity. This could result in higher borrowing costs and decreased access to various funding sources for the Issuer, which, in turn, could have an adverse effect on the Issuer's business, results of operations, financial position or prospects.

***Insolvency risks under Cypriot law***

The insolvency proceedings to which the Issuer could be subject to in Cyprus are (i) receivership, (ii) administration and (iii) winding up (a) by the court, (b) voluntarily by its shareholders or creditors or (c) subject to the supervision of the court. As the Notes are unsecured obligations, in the event of the



insolvency of the Issuer, Noteholders would be unsecured creditors of the Issuer (and each Noteholder would rank *pari passu* with each other) and, depending on the size of the insolvency proceeds recovered following such insolvency, each Noteholder may receive less than it would have expected to receive under the Notes (and this may be less than its initial investment).

***Risk factor relating to the ultimate shareholder of the Issuer***

The ultimate shareholder owning and controlling the Issuer is Oleg Mikhasenko, who is the sole ultimate beneficial owner of the Group. The Issuer does not have any specific measures in place to ensure that this position of control is not abused. If such position of control is abused, this could have a material adverse effect on the Issuer's financial condition, results of operations and future prospects which may, in turn, result in the Issuer being unable to fulfil its obligation to Noteholders under the Notes.

***Risks factors relating to the Russian Federation***

Economic, political and legal uncertainty in Russia could have a material adverse effect on the Issuer. A significant proportion of the Issuer's revenue is derived from Russian investors and, as such, a large number of the Issuer's counterparties are based in Russia. Instability in Russia (as further described in more detail in the risk factors below) could seriously impact Russian counterparties' ability to invest which could lead to a reduction in the Issuer's revenue. Any such reduction in revenue could potentially affect the Issuer's ability to make payments to Noteholders under the Notes in part or in full.

**KEY INFORMATION ON THE NOTES**

***What are the main features of the Notes?***

*Type, class and ISIN:*

The Notes are share linked notes issued as Series number 167, Tranche number 1. The Notes are issued in registered form and have the following ISIN Code: XS2333597859.

The Notes are linked to a basket of the following shares (each a "Share" and together the "Shares"):

- i. Biogen Inc (Bloomberg Code: BIIB UW Equity; ISIN: US09062X1037);
- ii. BioMarin Pharmaceutical Inc (Bloomberg Code: BMRN UW Equity; ISIN: US09061G1013); and
- iii. Helmerich & Payne Inc (Bloomberg Code: HP UN Equity; ISIN: US4234521015).

*Currency, denomination, par value, number of securities issued and duration:*

The Notes are denominated in U. S. Dollars ("USD"). The Notes have a maturity date of 30 April 2023 (the "**Maturity Date**"). As at the issue date of the Notes, there will be 1,200 Notes of the Series in issue. The Notes have a denomination of USD 1,250 per Note and an aggregate nominal amount of USD 1,500,000.

*Rights attached the Securities:*

***Status of the Notes***

The Notes constitute unsubordinated and unsecured obligations of the Issuer. The Notes constitute direct, general and unconditional obligations of the Issuer which rank at least *pari passu* with all other present and future unsecured obligations of the Issuer, save for such obligations as may be preferred by provisions of law that are both mandatory and of general application.

***Events of Default***

The terms of the Notes contain events of default including non-payment, non-performance or non-observance of the Issuer's obligations in respect of the Notes and the insolvency or winding up of the Issuer.



### ***Meetings***

The terms of the Notes contain provisions for calling meetings of holders of such Notes to consider matters affecting their interests generally. These provisions permit defined majorities to bind all holders, including holders who did not attend and vote at the relevant meeting and holders who voted in a manner contrary to the majority.

### ***Taxation***

All payments in respect of Notes will be made free and clear of withholding taxes of the Republic of Cyprus, as the case may be, unless the withholding is required by any law and/or regulation.

### ***Governing law***

The Notes, the Agency Agreement (as amended or supplemented from time to time) and the Deed of Covenant and any non-contractual obligations arising out of or in connection with the Agency Agreement (as amended or supplemented from time to time) and the Deed of Covenant are governed by, and shall be construed in accordance with English law.

### ***Interest***

The Notes pay interest determined by reference to the Shares. Interest, if any, will be payable on the Interest Period End Dates as the Interest Payment Dates for the Notes.

The Notes bear or pay interest on the basis of a "Snowball Digital Coupon Condition" with a memory effect. Any interest not paid in respect of a period may be paid at a later date if certain conditions are met.

In summary, if the Reference Value of the Worst Performing Share (the "**Worst Value**") in respect of an Interest Valuation Date is greater than or equal to 65%, Noteholders will receive an interest payment on the related interest payment date equal to (A) the Specified Denomination *multiplied by* (B) 2.5% per Interest Period. Noteholders will also receive on such interest payment date the sum of all unpaid interest amounts in respect of any previous interest payments at such rate. However, if the Reference Value of the Worst Performing Share in respect of such Interest Valuation Date is less than 65%, no interest amount is payable on such interest payment date.

Where:

"**Closing Value**" means the value of a Share at the close of trading on the relevant exchange in respect of a given trading day;

"**Initial Value**" means, for each Share, the lowest Closing Value from all of the Strike Days in the Strike Period;

"**Interest Period**" means each period from (and including) an Interest Period End Date (or the Issue Date in the case of the first Interest Period) to (but excluding) the next following Interest Period End Date (or the Maturity Date in the case of the last Interest Period);

"**Interest Period End Date**" 30 January, 30 April, 30 July and 30 October in each year, commencing on 30 July 2021 up to and including the Maturity Date (in each case subject to adjustment in accordance with the following business day convention);

"**Interest Valuation Date**" 23 January, 23 April, 23 July and 23 October in each year, commencing on 23 July 2021 up to and including 23 April 2023 (or, if any such day is not a scheduled trading day for a Share, the next following scheduled trading day);

"**Reference Value**" means the Closing Value in respect of a Share in respect of a relevant valuation date *divided by* the Initial Value in respect of such Share, expressed as a percentage;



“**Strike Period**” means each of the following Strike Days: 27 April 2021, 4 May 2021, 11 May 2021, 18 May 2021 and 25 May 2021 (or, if any such day is not a Scheduled Trading Day, the next following Scheduled Trading Day);

“**Specified Denomination**” means USD 1,250; and

“**Worst Performing Share**” means the Share with the lowest Reference Value in respect of a relevant Interest Valuation Date.

#### ***Early Redemption***

The Notes may be redeemed early for tax reasons at the early redemption amount calculated in accordance with the terms and conditions of the Notes. In addition, the Notes may be redeemed early following an automatic early redemption (see “*Automatic Early Redemption*” below).

The Notes may also be cancelled or redeemed early following the occurrence of certain disruption, adjustment, extraordinary or other events in relation to the Shares.

#### ***Automatic Early Redemption***

If the Reference Value in respect of the Worst Performing Share in respect of an Automatic Early Redemption Valuation Date is greater than or equal to Automatic Early Redemption Price, the Notes will be automatically redeemed at 100% of par.

“**Automatic Early Redemption Valuation Date**” means each Interest Valuation Date (except for the Interest Valuation Date scheduled to fall on 23 April 2023).

#### ***Final Redemption – Notes***

Each Note will be redeemed by the Issuer on the Maturity Date (unless previously redeemed or purchased and cancelled) at the Final Redemption Amount for Autocall Standard Notes.

In summary, if the Reference Value of the Worst Performing Share in respect of the last Interest Valuation Date is greater than or equal to 65%, the Notes will be redeemed at par. If the Reference Value in respect of the Worst Performing Share in respect of the last Interest Valuation Date is less than 65% (representing a decline of more than 35% from the Initial Value of such Worst Performing Share), Noteholders will receive a final redemption amount in USD equal to (A) the Specified Denomination multiplied by (B) the Reference Value in respect of the Worst Performing Share in respect of the last Interest Valuation Date (which shall be the Knock-in Determination Day and the SPS Redemption Valuation Date), with the result that the nominal amount invested by a Noteholder will be lost at a rate of 1% for every 1% that the Closing Value of such Worst Performing Share in respect of the last Interest Valuation Date is below the Initial Value of such Worst Performing Share.

#### ***Restrictions on free transferability of the securities:***

The Notes will be freely transferable, subject to the offering and selling restrictions in the Russian Federation, the Republic of Cyprus and under the Prospectus Regulation and the laws of any jurisdiction in which the relevant Notes are offered or sold.

#### ***Where will the securities be traded?***

Application has been made for the Notes to be admitted to the official list (the “**Official List**”) of Euronext Dublin and to trading on its regulated market (the “**Regulated Market of Euronext Dublin**”).

#### ***What are the key risks that are specific to the Notes?***

In addition to the risks relating to the Issuer (including default risk) that may affect the Issuer's ability to fulfil its obligations under the Notes, there are certain factors which are material for the purposes of assessing the market risks associated with Notes, including that (i) the Notes are unsecured obligations, (ii) the trading market for the Notes may be volatile and may be adversely impacted by many events, (iii) an active secondary market may never be established or may be illiquid and that this may adversely affect the value at which an investor may sell its Notes (investors may suffer a partial or total loss of the



amount of their investment), (iv) the trading price of the Notes is affected by a number of factors including, but not limited to, the price of the Shares and volatility and such factors mean that the trading price of the Notes may be below the Final Redemption Amount, (v) exposure to the Shares may be achieved by the Issuer entering into hedging arrangements and investors are exposed to the performance of these hedging arrangements and events that may affect the hedging arrangements and consequently the occurrence of any of these events may affect the value of the Notes, (vi) the occurrence of an additional disruption event or optional additional disruption event may lead to an adjustment to the Notes, or early redemption or may result in the amount payable on scheduled redemption being different from the amount expected to be paid at scheduled redemption and consequently the occurrence of an additional disruption event and/or optional additional disruption event may have an adverse effect on the value or liquidity of the Notes, and (vii) the meetings of Noteholders provisions permit defined majorities to bind all Noteholders. In addition, there are specific risks in relation to Notes which are linked to a basket of Shares and an investment in such Notes will entail significant risks not associated with an investment in a conventional debt security. Risk factors in relation to share linked Notes include similar market risks to a direct equity investment, potential adjustment events or extraordinary events affecting the shares and market disruption or failure to open of an exchange which may have an adverse effect on the value and liquidity of the Shares. In certain circumstances Noteholders may lose the entire value of their investment.

#### KEY INFORMATION ON THE OFFER OF THE NOTES TO THE PUBLIC AND THE ADMISSION TO TRADING ON A REGULATED MARKET

##### *Under which conditions and timetable can I invest in this security?*

The Notes are offered by way of private placement. This is not a public offer and the Issuer does not consent to the use of this Final Terms in connection with any public offer of the Notes.

The Issuer has appointed BrokerCreditService (Cyprus) Limited (the "**Dealer**") as the Dealer for the Programme. The arrangements under which Notes may from time to time be agreed to be sold by the Issuer to, and purchased or placed by, the Dealer is set out in the Dealer Agreement between the Issuer and the Dealer.

No expenses will be chargeable by the Issuer to an investor in connection with the issue of the Notes. Any expenses chargeable by the Dealer to an investor shall be changed in accordance with any relevant contractual arrangements between the Dealer and that investor.

##### *Who is the offeror and/or the person asking for admission to trading?*

BrokerCreditService (Cyprus) Limited (as the Dealer for the Programme). BrokerCreditService (Cyprus) Limited was incorporated in Cyprus on 7 December 2004, Registration Number HE 154856. Its registered office is at Spyrou Kyprianou & 1 Oktovriou, 1 VASHIOTIS KALANDE OFFICES, 2nd floor, Mesa Geitonia, 4004 Limassol, Cyprus.

##### *Why is the prospectus being produced?*

##### *The use and estimated net amount of the proceeds:*

The net proceeds from the issue of the Notes will be used for the general financing purposes of the Issuer. The offer of the Notes is not subject to an underwriting agreement.

##### *Conflicts of interest:*

Various entities within the Group (including the Issuer) may undertake different roles in connection with the Notes and may also engage in trading activities (including hedging activities) relating to the Shares and other instruments or derivative products based on or relating to the Shares which may give rise to potential conflicts of interest. In particular, the Calculation Agent is an affiliate of the Issuer. The Calculation Agent has no obligation to act in the best interests of the Noteholders and therefore a conflict of interest may arise between the Calculation Agent and Noteholders.